Open Collections

UBC Faculty Research and Publications

New drugs Therapeutics Initiative (University of British Columbia)

Description

Therapeutics Letter 13 reviews four newer drugs: losartan, lansoprazole, cefprozil, zuclopenthixol. Conclusions: Losartan, starting with a dose of 12.5 mg once daily, may be considered in patients who require an ACE inhibitor. Lansoprazole is a proton pump inhibitor which is similar to omeprazole in potency, pharmacokinetics, safety and effectiveness. Cefprozil is a new oral cephalosporin, which should be reserved for patients who are allergic or intolerant to the first or second line choices. Zuclopenthixol is a thioxanthene neuroleptic similar to flupenthixol. It has no distinctive advantages over haloperidol and other neuroleptics and should be reserved for selected patients who fail to respond or are intolerant to other neuroleptics.

Item Metadata

Title
New drugs
Alternate Title
Therapeutics Letter 13
Creator
Therapeutics Initiative (University of British Columbia)
Date Issued
1996-04
Description
Therapeutics Letter 13 reviews four newer drugs: losartan, lansoprazole, cefprozil, zuclopenthixol. Conclusions: Losartan, starting with a dose of 12.5 mg once daily, may be considered in patients who require an ACE inhibitor. Lansoprazole is a proton pump inhibitor which is similar to omeprazole in potency, pharmacokinetics, safety and effectiveness. Cefprozil is a new oral cephalosporin, which should be reserved for patients who are allergic or intolerant to the first or second line choices. Zuclopenthixol is a thioxanthene neuroleptic similar to flupenthixol. It has no distinctive advantages over haloperidol and other neuroleptics and should be reserved for selected patients who fail to respond or are intolerant to other neuroleptics.
Subject
Antipsychotic Agents; Cefprozil; Lansoprazole; Losartan; Omeprazole; Proton Pump Inhibitors
Genre
Other
Type
Text
Language
eng
Notes
The UBC TI is funded by the BC Ministry of Health to provide evidence-based information about drug therapy. We neither formulate nor adjudicate provincial drug policies.
Date Available
2023-06-20
Provider
Vancouver : University of British Columbia Library
Rights
Attribution-NonCommercial-NoDerivatives 4.0 International
DOI
10.14288/1.0433592
URI
http://hdl.handle.net/2429/85002
Affiliation
Medicine, Faculty of; Anesthesiology, Pharmacology and Therapeutics, Department of
Peer Review Status
Reviewed
Scholarly Level
Faculty; Researcher
Rights URI
http://creativecommons.org/licenses/by-nc-nd/4.0/
Aggregated Source Repository
DSpace

Item Media

Item Citations and Data

Rights

Attribution-NonCommercial-NoDerivatives 4.0 International